Geron (GON) Stock Price & Analysis
GON Stock Chart & Stats
- Day’s Range
- EUR 0.84 - EUR 0.84
- 52-Week Range
- EUR 0.84 - EUR 1.63
- Previous Close
- EUR 0.87
- Volume
- 0
- Average Volume (3M)
- 447
- Market Cap
- EUR 512.80M
- Enterprise Value
- EUR 807.52M
- Total Cash (Recent Filing)
- EUR 300.85M
- Total Debt (Recent Filing)
- EUR 122.14M
- Price to Earnings (P/E)
- ―
- Beta
- 0.77
- Next Earnings
- Nov 04, 2026 (Est.)
- EPS Estimate
- -0.01
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
RYTELO Revenue And Adoption Growth
Growing RYTELO revenue alongside expansion in prescribing accounts indicates increasing commercial adoption in the lower-risk MDS market. Continued demand growth and management’s expectation of reaching the mid- to high-end of 2026 guidance support a developing revenue base over the next several quarters.
Improving Operating Leverage
Revenue growth materially outpacing operating-expense growth demonstrates improving operating leverage as the commercial franchise scales. If this relationship persists, it can reduce the cost burden of expansion and provide a clearer path toward improved operating profitability without requiring equivalent increases in spending.
Stronger Capital Structure
Very low debt relative to equity gives Geron greater financial flexibility than in the prior year, while its cash and securities provide resources for commercial investment and clinical programs. This stronger capital structure can help support execution through the product’s growth phase and reduce near-term financing pressure.
Bears Say
Persistent Cash Burn
Deeply negative operating and free cash flow show that the business is not yet self-funding despite commercial revenue growth. Continued cash burn can consume financial resources, increase reliance on external funding or balance-sheet reserves, and constrain the company’s ability to invest across commercial and clinical priorities.
Ongoing Net Losses
Geron remains unprofitable even as revenue scales, indicating that product growth has not yet covered development, commercial, and corporate costs. Sustained net losses can delay internally generated capital formation and leave future profitability dependent on continued adoption, expense control, and successful operating leverage.
Myelofibrosis Program Setback
Discontinuing IMpactMF removes a major clinical opportunity from the development portfolio after the study was judged unlikely to meet its primary endpoint. The setback narrows imetelstat’s potential beyond lower-risk MDS, increases reliance on RYTELO execution, and weakens diversification within the pipeline.
Geron News
Geron Lawsuit Ruling: Court Allows Investor Claims Over Rytelo Sales Statements to Move Forward
A federal judge in California has denied the defendant’s motion to dismiss an investor lawsuit alleging that the company and certain executives made false or misleading statements about Rytelo’s commercial
GON FAQ
What was Geron’s price range in the past 12 months?
What is Geron’s market cap?
When is Geron’s upcoming earnings report date?
How were Geron’s earnings last quarter?
Is Geron overvalued?
Does Geron pay dividends?
What is Geron’s EPS estimate?
How many shares outstanding does Geron have?
What happened to Geron’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Geron?
What is the TipRanks Smart Score and how is it calculated?
Geron Stock Smart Score
Company Description
Geron
Geron Corporation is an advanced-stage biopharmaceutical company dedicated to the creation and market introduction of treatments for myeloid blood cancers. Its primary drug candidate, imetelstat, is a telomerase inhibitor currently undergoing Phase 3 clinical evaluation. This therapy aims to suppress the unchecked proliferation of cancerous stem and progenitor cells characteristic of myeloid hematologic malignancies. Imetelstat is being developed to address low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. Established in 1990, Geron's corporate headquarters are located in Foster City, California.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Harout Semerjian
- Employees
- 258
- Website
- www.geron.com
- Address
- 919 East Hillsdale Boulevard, Foster City, CA, 94404, US
Geron (GON) Earnings & Revenues
GON Earnings Call
Earnings Call SentimentPositive
Overall the call conveyed positive commercial momentum and strengthening scientific evidence for RYTELO and the myelofibrosis program, supported by revenue growth (Q2 $57.5M, +17% YoY, +11% QoQ), expanding accounts and encouraging real-world data. The company also highlighted operational discipline (H1 operating expense down ~4% vs H1 revenue +24%) and a solid cash position ($327M). Counterbalancing these positives are rising gross-to-net deductions (20.7% in Q2 vs 15.3% prior year), a modest quarter-over-quarter cash decline, ongoing investment-driven spending, uncertainty around interim analysis modifications for IMpactMF, and unresolved EU pricing/MFN complexities that could affect ex-U.S. expansion. On balance the favorable revenue, evidence generation, and execution momentum outweigh the manageable risks and uncertainties.
View all DE:GON earnings summariesGON Stock 12 Month Forecast
Average Price Target
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 6 | 1 | 15 |
| Technical Analysis | 6 | 1 | 3 |
| Moving Averages | 0 | 0 | 12 |